BridgeBio Pharma BBIO Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's other working capital?
- BridgeBio Pharma (BBIO) reported other working capital of -$306K in Q1 2026.
- How has BridgeBio Pharma's other working capital changed year-over-year?
- BridgeBio Pharma's other working capital decreased by 1557.1% year-over-year, from $21K to -$306K.
- What is the long-term trend for BridgeBio Pharma's other working capital?
- Over 2 years (2021 to 2023), BridgeBio Pharma's other working capital has grown at a -66.9% compound annual growth rate (CAGR), from -$7.32M to $803K.
- What does other working capital mean?
- The net change in miscellaneous short-term operating assets and liabilities.
- How do you interpret other working capital?
- Fluctuations reflect timing differences in operational payments and receipts; consistent negative values may indicate inefficient working capital management.
- How does other working capital compare across companies?
- Standard line item across all industries, though magnitude varies based on operational complexity.